Navigation Links
Cytotoxic in Medical Technology

Pharmatek's Highly-Potent and Cytotoxic (HP/C) Facility Positions It as Industry Leader in Development and Manufacturing of HP/C Compounds

... Effectiveness Of New Highly-Potent And cytotoxic (HP/C) Facility Through Airborne Particulate ... and manufacturing of highly-potent and cytotoxic compounds. "The testing results of our HP/C ... services to include highly potent and cytotoxic compounds, and do it in the safest possible way," ...

Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress

... a disease-specific antigen can induce both cytotoxic T-cell and antibody (B-cell) immune responses against that antigen. cytotoxic T-cells, also referred to as CD8 T-cells, are ... near future; Poly-ICR's ability to induce both cytotoxic and antibody immune responses; and our ...

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

... first drug in a clinical study that targets the cytotoxic activity of doxorubicin specifically to ... of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product ... the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. ...

Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab

... may relate to the high anti-tumor activity of cytotoxic T cells recruited by blinatumomab," commented ... These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ... class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer ...

Nventa Develops Proprietary Vaccine Adjuvant

... a disease-specific antigen can induce both cytotoxic (T-cell) and antibody (B-cell) immune responses against that antigen. cytotoxic T-cells, also referred to as CD8 T-cells, are ... vaccines; Poly-ICR's ability to induce both cytotoxic and antibody immune responses; our expectation ...

Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research

... can be delivered subcutaneously, and show that cytotoxic T cell activity is not impaired by long-term BiTE ... These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ... class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful ...

Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer

... of a physician qualified in the use of cytotoxic anti-cancer therapy. Malignant pleural ... is given in combination with other cytotoxic agents; most of these patients had pre-existing ... (Usually when given in combination with other cytotoxic agents and with pre-existing cardiovascular ...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

... convenience." About temozolomide TEMODAL (temozolomide), a cytotoxic agent, is currently approved in oral form as 5mg, 20mg, 100mg, 140mg, 180mg and 250mg capsules in Europe. cytotoxic agents are designed to impact the replication of cells that divide ...

Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells

... autoimmune diseases, presented data from a preclinical study(1) showing cytotoxic activity of anti-EpCAM antibody adecatumumab (MT201) against KRAS-mutated ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...

Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma

... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...

Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas

... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...

Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors

... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...

Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study

... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...

Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma

... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...

Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies

... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...

Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future

... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... a new class of therapeutic antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in ...

Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress

... The observed antioxidant activity of ONCONASE may be important to its cytotoxic effect on cancer cells and mechanistic synergism with other anti-cancer ... from unresectable malignant mesothelioma. "The data further confirm the cytotoxic effect of ONCONASE on cancer cells," said Kuslima Shogen, Alfacell's ...

Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML

... greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 ... do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent which should not be given to healthy volunteers, this evaluation is ...

National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness

... second-generation DNA minor groove binder, has shown potent cancer killing activity, and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies, in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor ...

CuraGen Updates CR011-vcMMAE Data at ASCO

... mg/kg administered intravenously once every three weeks. Eligible patients had progressive disease at trial entry and may have received one prior cytotoxic regimen and any number of prior immunotherapies. Of the patients enrolled, 94% had Stage IV disease of which two-thirds were classified as M1c, the ...

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

... (3) Natale, R. et al. Vandetanib versus erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) after failure of at least 1 prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). ABS 31610. ASCO. 2009. (4) Ferlay, J. et al. GLOBOCAN 2002: Cancer Incidence, ...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

... Presenter: Elena G. Chiorean, MD Location: Level 2 - West Hall C. Poster Session Track: #79 Developmental Therapeutics: cytotoxic Chemotherapy; Poster Board B19 (Abstract # 2558) About SF1126 SF1126 is the only clinical stage vascular targeted ...

FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway

... that AR-12 is active in a wide range of tumor types and it also shows promising activity in combination with several widely used approved cytotoxic as well as molecularly targeted anti-cancer agents," stated Dr. Roger G. Berlin, Chief Executive Officer of Arno. About AR-12 AR-12 is a ...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

... cell lung cancers (SCLC). In in vitro preclinical studies, a fully human, non-fucosylated anti-fucosyl-GM1 antibody, MDX-1110, demonstrated robust cytotoxic effector function (both antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity) for killing tumor cells. Additionally, ...

First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

... EP-100 was fast-acting, destroying LHRH receptor over-expressing OVCAR-3 cells within an hour compared to the unconjugated CLIP 71 which was less cytotoxic and was slow-acting (p<0.005). LHRH receptor negative SKOV-3 cells were significantly less sensitive to EP-100 than OVCAR-3 cells and the effects ...

Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin

... second-generation DNA minor groove binder, has shown potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor ...

DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round

... inhibit their repair during the treatment period. Thus siDNA increases the effectiveness of radiotherapy and chemotherapy without adding any cytotoxic effect. The company possesses a portfolio of exclusive worldwide licenses resulting from the pioneering work of its founding scientists at the ...

New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer

... the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... been treated with KRX-0401 in trials conducted both in the United States and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. It does not appear to cause myelosuppression (depression of the immune system that may lead to life threatening infections), ...

Sosei Confirms the Safety of SD118 in Two Phase I Trials

... compression. Also, it is a common secondary symptom in diseases like diabetes, cancer and herpes zoster infection, and can occur after the use of cytotoxic drugs. The condition has a poor prognosis and is a significant cause of morbidity. The neuropathic pain market is forecast to reach US$5.5 billion by ...

Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey

... melanoma. Patients may have been previously treated with surgery, adjuvant therapy, and/or biotherapy, but cannot have been previously treated with cytotoxic chemotherapy. The patients will be randomized on a 2:1 basis: approximately 250 patients will be treated with Allovectin-7(R) and approximately 125 ...

Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer

... The Phase 2 clinical trial is currently enrolling 80 women diagnosed with advanced, measurable breast cancer who have received no more than two prior cytotoxic cancer therapies. The Principle Investigator of the trial is Dr. Charles Shapiro, Director of Breast Oncology at Ohio State University. The trial ...

CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma

... mg/kg administered intravenously once every three weeks. Eligible patients had progressive disease at trial entry and may have received one prior cytotoxic regimen and any number of prior immunotherapies. Of the patients enrolled, 94% had Stage IV disease of which two-thirds were classified as M1c, the ...

Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy

... trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in ...

RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

... multi-center, open label, stratified study of RAD001 in 160 patients with advanced pancreatic NET, who became resistant to prior treatment with cytotoxic chemotherapy. In the monotherapy treatment group, 115 patients received RAD001 alone. In the combination treatment group, 45 patients whose tumors ...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

... the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). Therefore, it would appear that the L.E.A.P.S.(TM) construct represents a chimeric peptide with bi-functional behavior. ...

Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies

... the exclusivity of the surface expression of HAAH to cancer cells, suggests the potential clinical utility of PAN-622 for the specific delivery of cytotoxic agents to cancer cells. About Panacea Pharmaceuticals, Inc. Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused ...

September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging

... properties of corticosteroid medications such as prednisone and methylprednisolone often improve symptoms within days. Immune-suppressing and cytotoxic drugs are used when vasculitis is severe and does not respond to corticosteroids. Thanks to drug treatments, some types of vasculitis that were ...

Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma

... synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor ...

M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics' MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases

... with CUP pose a therapeutic dilemma and treatment is often empiric with a "trial and error" approach. In the era of rapidly growing effective cytotoxic and targeted therapies for known cancers, quicker and more accurate methods of identifying the tissue of origin of CUP cases would permit the use of ...
Other Contents
(Date:9/18/2014)... Wis. No matter how many times it,s ... social, communicating creatures. , But by using ... organisms radically alter their behavior to suit their ... of them are present, and act accordingly. , ... millions, it may change from innocuous to pathogenic, ...
(Date:9/18/2014)... turned its newborn screening program into a model other states ... the first-ever Newborn Screening Quality Award from the March of ... M.P.H., Arizona,s Department of Health Services director, with the award ... policy of full transparency for the length of time it ... lab for analysis, and set a target of having 95 ...
(Date:9/18/2014)... global cycles of carbon and nitrogen comprise all ... and environmental systems have caused imbalances and perturbations ... gases (GHGs). Increased GHGs result in climate changes ... ecosystems, oceans and the atmosphere. Understanding these feedback ... branch of environmental science during the past three ...
Breaking Biology News(10 mins):Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Greenhouse gas research enters a new era 2
(Date:9/20/2014)... Ticket Down is a reputable source for ... ticket exchange is offering their customer appreciation promo code ARIANA-2015 ... step in the entertainment business. The 21-year-old from Boca Raton, ... entertainment business, but is closing in on “Pop Diva” status. ... will hit the road next year on the “Honeymoon Tour,” ...
(Date:9/20/2014)... Lifeinsurancequoteterm.net has released a new ... exam life insurance plan provides for vulnerable family members. ... should be a top priority for every provider. It ... taking medical examinations and visiting a doctor. , ... will provide coverage up to $300,000, but only to ...
(Date:9/20/2014)... NY (PRWEB) September 20, 2014 Ticket ... Grande concert tickets for her 2015 “Honeymoon Tour.” ... code ARIANA-2015 for added savings. , In early 2015, fans ... stars in the world across North America. Twenty-one-year-old Ariana Grande ... Tour,” which will take her to 25 cities across the ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA ... its new website. The new site provides the ... products for customers. Here, people can find a ... decision. Also, it has recommended some excellent web ... of the great web hosting suppliers, InMotion ( ...
(Date:9/20/2014)... 20, 2014 Recently, UWDress.com, an innovative ... women’s special occasion outfits, has launched a special offer ... prom outfits are popular among worldwide clients. Now, all ... prom dresses on its website. , Additionally, ... from around the world. Great custom made items can ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 2Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 3Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 3Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2
Other TagsOther Tags